SCHEMBL25238546

SCHEMBL25238546

CC(C)(C)OC(=O)Nc1ccc(-c2ccc(F)cc2)cc1NC(=O)c1ccc(S(C)(=O)=NC2CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MMP8 P22894 4/20 0.40
▸ MMP3 P08254 2/20 0.40
▸ HDAC1 Q13547 3/20 0.40
▸ RORC P51449 3/20 0.38
▸ KCNQ4 P56696 1/20 0.38
▸ KCNQ5 Q9NR82 1/20 0.38
▸ HDAC2 Q92769 3/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ MET P08581 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ LTK P29376 1/20 0.38
▸ GRK5 P34947 1/20 0.38
▸ MAP2K2 P36507 1/20 0.38
▸ CDK8 P49336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25211166 0.89 CYP17A1 (0.43) CYP17A1KDM4EALDH1A1KMT2AHSD17B10
SCHEMBL25256259 0.89 CYP17A1 (0.43) CYP17A1KDM4EALDH1A1KMT2AHSD17B10
SCHEMBL25255025 0.89 CYP17A1 (0.43) CYP17A1KDM4EALDH1A1KMT2AHSD17B10
SCHEMBL25214558 0.86 CYP17A1 (0.44) CYP17A1KDM4EALDH1A1KMT2AHSD17B10
SCHEMBL25214954 0.85 MMP8 (0.36) CYP17A1KMT2AMMP8MMP3HDAC1
SCHEMBL25219058 0.85 TP53 (0.37) CYP17A1KMT2AMMP8MMP3HDAC1
SCHEMBL25216889 0.84 CYP17A1 (0.41) CYP17A1KDM4EALDH1A1KMT2AHSD17B10
SCHEMBL25214971 0.83 CYP17A1 (0.46) CYP17A1KDM4EALDH1A1KMT2AHSD17B10
SCHEMBL25249960 0.82 HDAC2 (0.57) HDAC1HDAC2CHEK1NTRK1MET
SCHEMBL25224047 0.82 HDAC1 (0.43) CYP17A1KDM4EALDH1A1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 1294/4885KDM4E 308/4885ALDH1A1 495/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 657/4885KDM4E 301/4885ALDH1A1 477/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 CYP17A1 657/4885KDM4E 301/4885ALDH1A1 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback